‘Leaps of Faith:’ ICER Meeting Suggests Reimbursement Hurdles For NASH Drugs

Lack of long-term clinical outcomes data on a slowly progressing, common condition combined with a rapidly changing treatment space for obesity and health system cost issues may present problems for two NASH treatments even if they win accelerated approval from US FDA.